Clinical trial NCT01413893: An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors
Official title: An Extension Study of Linifanib in Subjects With Advanced or Metastatic Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Advanced Solid Tumors
Lead sponsor: AbbVie
Sponsor class: INDUSTRY
First posted: 2011-08-10
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: An extension study of linifanib in subjects with advanced or metastatic solid tumors.

Detailed description: This study is designed to evaluate the safety of linifanib in subjects with advanced or metastatic solid tumors.

Eligibility criteria: Inclusion Criteria

1. Subject has completed a previous study utilizing linifanib (per the criteria in the previous study) or was active and assigned to linifanib when the study was completed and the investigator believes that continued treatment with linifanib is in the best interest of the subject.
2. Women of childbearing potential and men must agree to use adequate contraception (one of the following listed below) prior to study entry, for the duration of study participation and up to 90 days following completion of therapy. Women of childbearing potential must have a negative urine pregnancy test within 7 days prior to initiation of treatment and/or post menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential:

   * total abstinence from sexual intercourse (minimum one complete menstrual cycle);
   * vasectomized partner(s);
   * Hormonal contraceptives (oral, parenteral or transdermal) for at least 3 months prior to study drug administration; if the subject is currently using a hormonal contraceptive, she should also use a barrier method during this study and for 1 month after study completion;
   * intrauterine device (IUD);
   * double-barrier method (condoms, contraceptive sponge, diaphragm or vaginal ring with spermicidal jellies or creams);
   * Additionally, male subjects (including those who are vasectomized) whose partners are pregnant or might be pregnant must agree to use condoms for the duration of the study and for 90 days following completion of therapy.
3. Is capable of understanding and complying with parameters as outlined in the protocol and able to sign the informed consent, approved by an Independent Ethic Committee (IEC)/Institutional Review Board (IRB) prior to the initiation of any screening or study-specific procedures.

Exclusion Criteria

1. Subject discontinued linifanib administration before completing the prior study (due to disease progression, toxicity, withdrawal of consent, other).
2. Subject has any medical condition which in the opinion of the investigator places the subject at an unacceptably high risk for toxicities.
3. Subject is a lactating or pregnant female.

Primary outcomes:
measure: Safety: Adverse Events - The number of participants with adverse events will be reported as a measure of Safety.
timeFrame: All adverse events occuring through the Final Visit will be reported.
measure: Safety: Physical Examination and Vital Signs - Physical examination will be performed and vital signs will be assessed for participants as a measure of safety.
timeFrame: Change from baseline to Day 1 of Weeks 1, 2, 3, 6, 9 and 12 and on Week 24 then Day 1 of every 12 weeks and Final Visit.
measure: Safety: Multiple Gated Acquisition (MUGA) will be assessed at specified time points as a measure of safety.
timeFrame: Change from baseline to every 12 weeks
measure: Safety: Clinical Lab Tests will be performed for each participant as a safety measure.
timeFrame: Change from baseline to Day 1 of Weeks 1, 2, 3, 6, 9 and 12 and on Week 24 then Day 1 of every 12 weeks and Final Visit
Secondary outcomes:
measure: There are no secondary outcome measures specified for this study.
timeFrame: There are no secondary outcome measures specified for this study.
Other outcomes:
Locations:
Study officials:
affiliation: Abbott
name: Mark D. McKee, MD
role: STUDY_DIRECTOR
References: